357 related articles for article (PubMed ID: 21467949)
1. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
3. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
6. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
[TBL] [Abstract][Full Text] [Related]
7. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
8. Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine.
Fink C; Bock M; Kiessling F; Lichy MP; Krissak R; Zuna I; Schmähl A; Delorme S; Kauczor HU
J Magn Reson Imaging; 2004 Feb; 19(2):202-8. PubMed ID: 14745754
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
[TBL] [Abstract][Full Text] [Related]
10. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer].
Li ZL; Chen X; Xia CC; Sun JY; Li CX; Tang HH; Song B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 43(4):601-4. PubMed ID: 22997905
[TBL] [Abstract][Full Text] [Related]
12. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J; Saini S; Mitchell DG; Davis PL; Johnson CD; Kuhlman JE; Parisky YR; Runge VM; Weinreb J; Bernardino ME
AJR Am J Roentgenol; 1995 Nov; 165(5):1157-61. PubMed ID: 7572495
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
14. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.
Essig M; Lodemann KP; Le-Huu M; Brüning R; Kirchin M; Reith W
Invest Radiol; 2006 Mar; 41(3):256-63. PubMed ID: 16481908
[TBL] [Abstract][Full Text] [Related]
15. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.
Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M
Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine.
Runge VM; Bronen RA; Davis KR
Invest Radiol; 1992 Aug; 27 Suppl 1():S22-32. PubMed ID: 1506150
[TBL] [Abstract][Full Text] [Related]
17. [Safety and use of gadobutrol in patients with brain tumors (phase III trial)].
Lemke AJ; Sander B; Balzer T; Geens V; Hosten N; Felix R
Rofo; 1997 Dec; 167(6):591-8. PubMed ID: 9465954
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of gadoteridol for contrast-enhanced magnetic resonance imaging in children.
Ball WS; Parker JR; Davis PC; Glasier CM; Morris MR
Invest Radiol; 1992 Aug; 27 Suppl 1():S45-52. PubMed ID: 1506153
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
20. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
